Merck drug sacituzumab tirumotecan reduces death risk in advanced endometrial cancer
Merck and Kelun-Biotech reported that their new chemotherapy cut the risk of death by one-third for patients with advanced endometrial cancer at a study presentation in Madrid.
Study results presented Monday
Randomized Phase 3 study results showed the targeted chemotherapy lowered mortality rates significantly. The specific medication is known as sacituzumab tirumotecan or sac-TMT. This treatment has already received approval in China for multiple cancer types.
Global trials support approvals
Merck is currently running 18 global Phase 3 studies to support regulatory approvals outside China. Ten of these specific trials focus on women's cancers including endometrial cancer. The company aims to gain approval in the United States and Europe.
Revenue strategy for Merck
The drug helps replace revenue that will be lost when Keytruda loses patent protection in 2028. Kelun conducted the initial studies where the drug demonstrated survival-extending benefits. These findings are exclusive to STAT+ subscribers.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.